Invivyd announces peer-reviewed publication using CANOPY trial data

Invivyd (IVVD) announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY clinical trial of Invivyd’s monoclonal antibody pemivibart to predict clinical protection levels from COVID purely from laboratory-determined serum monoclonal antibody activity levels, irrespective of virus variation. This newly published analysis builds on similar, earlier peer-reviewed analyses demonstrating similar findings from pre-Omicron virus variants with a prior Invivyd antibody. “Our perspective at Invivyd from the beginning of the COVID pandemic through today is clear: we believe that once the safety of an Invivyd COVID monoclonal antibody that targets a stable epitope on the virus has been established, one can reliably estimate its ability to prevent COVID disease directly from its laboratory-assessed antiviral activity,” said Robert Allen, Ph.D., Chief Scientific Officer at Invivyd. “As we continue to develop this field, our hope is that healthcare professionals, policymakers, and regulators will recognize the demonstrated consistent responsiveness of SARS-CoV-2 to our highly active monoclonal antibodies, irrespective of virus variation, which may enhance the development and use of new monoclonal antibody options for patients in need, if approved.”